10-K/APeriod: FY2011

DEXCOM INC Annual Report (Amendment), Year Ended Dec 31, 2011

Filed March 28, 2012For Securities:DXCM

Summary

This 10-K filing from Dexcom, Inc. (DXCM) for the fiscal year ended December 31, 2011, highlights the company's growth trajectory and its strategic focus on expanding product revenue while managing operating losses. The company reported a significant increase in product revenue, reaching approximately $65.9 million, a 64% jump from the previous year, demonstrating strong commercial performance and market adoption. Dexcom's executive compensation strategy for 2011 emphasized conserving cash by favoring equity-based incentives over cash salaries, aiming to align employee interests with long-term stockholder value and support the company's goal of achieving profitability. The filing also details the company's corporate governance structure, board of directors, and executive compensation policies, including details on base salaries, bonus plans, and equity awards, reflecting a pay-for-performance philosophy. The robust board composition, with a majority of independent directors, and the clear committee structures underscore a commitment to sound governance.

Financial Statements
Beta

Key Highlights

  • 1Product revenue increased by 64% year-over-year to approximately $65.9 million in fiscal year 2011, indicating strong market traction and sales growth.
  • 2The company is focused on achieving profitability, evidenced by efforts to decrease operating losses while simultaneously increasing revenue.
  • 3Executive compensation strategy prioritizes equity incentives over cash to conserve cash resources and align management interests with stockholders.
  • 4Dexcom has a diverse and experienced board of directors, with a majority of independent directors, overseeing corporate governance and risk.
  • 5The company's compensation committee uses a peer group analysis to set executive pay, targeting median compensation but rewarding outstanding performance with above-median payouts.
  • 6Restricted Stock Units (RSUs) are a primary vehicle for long-term incentives and employee retention, favored over stock options to manage dilution.
  • 7The audit committee actively oversees financial reporting and risk management, with the board appointing Dr. Jonathan Lord as an 'audit committee financial expert'.

Frequently Asked Questions

In fiscal year 2011, Dexcom reported a significant increase in product revenue, reaching approximately $65.9 million. This represents a substantial growth of 64% compared to the $40.2 million reported in 2010.

Dexcom's executive compensation strategy for 2011 focused on conserving cash by emphasizing equity-based incentives (like Restricted Stock Units) over higher base salaries or cash bonuses. This approach aims to align executive interests with long-term stockholder value and support the company's goal of achieving profitability. Compensation is tied to performance against financial and operational goals.

Dexcom's Board of Directors is composed of experienced individuals with diverse backgrounds in healthcare, technology, and finance. A majority of the directors are considered independent, ensuring robust oversight. The Board has an Audit Committee, a Compensation Committee, and a Nominating and Governance Committee, each with specific responsibilities.

While focusing on revenue growth, Dexcom also prioritized decreasing its operating loss in 2011. This is reflected in their compensation structure, which included operating loss targets as a component of the annual bonus plan, incentivizing management to improve financial performance and move towards profitability.